Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenal Gland Disorders01:27

Adrenal Gland Disorders

2.3K
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

876
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
876
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

253
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
253
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

488
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
488
Hormones of the Adrenal Glands01:31

Hormones of the Adrenal Glands

3.4K
Adrenal hormones play a pivotal role in maintaining the body's electrolyte balance and orchestrating responses to stress, showcasing the intricate functions of the adrenal cortex and medulla.
The adrenal cortex, a powerhouse of hormone synthesis, generates over two dozen corticosteroid hormones. The zona glomerulosa produces mineralocorticoids, exemplified by aldosterone, influencing the electrolyte composition of body fluids. The synthesis of glucocorticoids such as cortisol and...
3.4K
Hypothalamic-Pituitary Axis01:37

Hypothalamic-Pituitary Axis

63.3K
The response to stress—be it physical or psychological, acute or chronic—involves activation of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is part of the neuroendocrine system because it involves both neuronal and hormonal communication. Its function is to regulate homeostatic systems—metabolic, cardiovascular, and immune—providing the necessary means to respond to a stressor.
63.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determinants of Quality of Life in Patients with Immune-Checkpoint-Inhibitor Induced Secondary Adrenal Insufficiency.

The Journal of clinical endocrinology and metabolism·2026
Same author

Presentation and Clinical Patterns of Bilateral Adrenal Lesions: A Retrospective Cohort Study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Impact of diagnosis and targeted interventions on the quality of life and neuropsychiatric outcomes of patients with adrenal tumours: a systematic review.

European journal of endocrinology·2026
Same author

Impact of Mild Autonomous Cortisol Secretion on Bone Density, Metabolism, and Microstructure: A Cross-sectional Study.

The Journal of clinical endocrinology and metabolism·2026
Same author

Characterization of adrenal masses in young adults at a tertiary care academic medical center.

Journal of the Endocrine Society·2026
Same author

Glucocorticoid reduction after starting crinecerfont in adult patients with classic CAH: practical perspectives.

The Journal of clinical endocrinology and metabolism·2026

Related Experiment Video

Updated: Oct 29, 2025

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.9K

Glucocorticoid induced adrenal insufficiency.

Alessandro Prete1, Irina Bancos2

  • 1Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK.

BMJ (Clinical Research Ed.)
|July 13, 2021
PubMed
Summary

Synthetic glucocorticoids can cause adrenal insufficiency, a condition impacting the hypothalamic-pituitary-adrenal axis. This review details risks, management strategies, and patient education for glucocorticoid-induced adrenal insufficiency (GI-AI).

More Related Videos

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.8K
Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.3K

Related Experiment Videos

Last Updated: Oct 29, 2025

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
08:02

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

9.9K
A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

23.8K
Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions
04:33

Primary Culture of Rat Adrenocortical Cells and Assays of Steroidogenic Functions

Published on: March 12, 2019

8.3K

Area of Science:

  • Endocrinology
  • Pharmacology
  • Internal Medicine

Background:

  • Synthetic glucocorticoids are vital for anti-inflammatory and immunosuppressive therapies.
  • A significant risk associated with glucocorticoid use is the suppression of the hypothalamic-pituitary-adrenal (HPA) axis, potentially leading to adrenal insufficiency.
  • Glucocorticoid-induced adrenal insufficiency (GI-AI) and associated withdrawal syndromes pose clinical challenges.

Purpose of the Study:

  • To review factors contributing to the risk of GI-AI.
  • To propose a standardized glucocorticoid tapering regimen.
  • To provide guidance on assessing adrenal function recovery and managing withdrawal syndromes.

Main Methods:

  • Comprehensive literature review on glucocorticoid therapy, HPA axis suppression, and adrenal insufficiency.
  • Analysis of factors influencing GI-AI risk, including dose, duration, and drug interactions.
  • Development of a proposed glucocorticoid taper protocol and assessment strategies for adrenal recovery.

Main Results:

  • Identified key risk factors for GI-AI: therapy duration, dose, potency, administration route, drug interactions, and individual susceptibility.
  • Highlighted the overlap in symptoms between glucocorticoid withdrawal, underlying conditions, and GI-AI.
  • Emphasized the need for careful tapering and patient counseling to prevent complications.

Conclusions:

  • Effective management of GI-AI requires a thorough understanding of risk factors and a structured approach to glucocorticoid tapering.
  • Adrenal function recovery must be confirmed before complete cessation of glucocorticoid therapy.
  • Improved patient and provider education is crucial for managing GI-AI and glucocorticoid withdrawal.